Why Some Men Don’t Respond to ED Pills but Respond to PRP?
He had followed every instruction carefully. The tablets came first, prescribed after an awkward but necessary conversation with his GP. He took them on an empty stomach, avoided alcohol, waited the recommended time. At first, there was hope—some response, a hint of improvement. But over the following months, that response faded. Increasing the dose did little. Trying a different brand changed nothing. What unsettled him most was not just the lack of effect, but the sense that something deeper had shifted. When he eventually heard about PRP and the p shot London clinics were offering, it sounded improbable. Yet for some men in his position, it appears to work where tablets do not.
Erectile dysfunction does not follow a single pathway, and that explains why a single class of treatment cannot suit every patient. Oral medications such as sildenafil or tadalafil act on a very specific mechanism: they enhance the nitric oxide pathway, improving blood flow into the penile tissue during arousal. When this pathway functions adequately but needs support, tablets can be highly effective. However, in men who do not respond, the issue often lies beyond simple vascular dilation. Structural changes in the penile tissue, reduced nerve sensitivity, endothelial damage, or long-standing metabolic conditions such as diabetes can all blunt the effect of tablets. In those cases, increasing dosage rarely solves the problem because the underlying biology no longer responds as expected.
This is where interest in the p shot, also referred to as the priapus shot or pshot, has grown. Rather than relying on pharmacological stimulation at the moment of arousal, PRP (platelet-rich plasma) therapy attempts to influence tissue health itself. The process involves drawing a small sample of the patient’s blood, concentrating the platelets, and re-injecting that plasma into targeted areas of the penis. Platelets contain growth factors that play a role in tissue repair, angiogenesis, and cellular signalling. In theory, and increasingly in practice, this may improve microvascular circulation and tissue responsiveness over time.
The distinction matters. A man who fails to respond to tablets often assumes that all treatments will fail in the same way. Yet the mechanism behind a penis shot differs fundamentally from that of oral medication. Tablets act temporarily; PRP aims to induce gradual biological change. This explains why some non-responders to medication report improvements after p shot treatment, particularly when their erectile dysfunction links to tissue quality rather than purely blood flow dynamics.
Clinical guidance from bodies such as NICE and the European Association of Urology continues to prioritise established treatments, including lifestyle modification, oral medication, vacuum devices, and, in more severe cases, injectable drugs or implants. PRP does not yet sit within standard first-line recommendations, largely because long-term, large-scale studies remain limited. However, smaller studies and emerging clinical experience suggest a role in selected patients—especially those who fall into the frustrating category of partial or non-responders.
That frustration deserves attention in its own right. Men who do not respond to tablets often cycle through escalating doses, different brands, and conflicting advice. The psychological toll builds quietly. Confidence erodes, and relationships can strain under the weight of repeated disappointment. By the time they explore alternatives such as p injection therapies, they often carry both scepticism and fatigue. This context matters when evaluating outcomes. A modest physiological improvement can translate into a meaningful change in quality of life if it restores a sense of reliability.
Cost, inevitably, enters the conversation. The priapus shot price in London varies widely, and patients frequently question what justifies the higher end of the range. The answer lies less in the injection itself and more in how the procedure is delivered. Clinics that use CE-marked centrifuge systems, apply ultrasound guidance, and rely on clinicians with formal surgical or anatomical training tend to charge more. These elements influence precision, safety, and potentially outcomes. When people search for male enlargement injections cost UK or compare options labelled as penile injection growth, they often encounter a confusing mix of claims. It becomes important to distinguish between medically grounded PRP protocols and loosely defined “enhancement” treatments that may lack standardisation.
The language surrounding these procedures does not always help. Terms like penis shot or p-shot before and after circulate widely online, often accompanied by anecdotal accounts or selectively presented images. While some patients do report visible changes, clinicians generally frame PRP as a functional treatment rather than a purely aesthetic one. Improvements in erection quality, sensitivity, or stamina tend to carry more clinical weight than changes in size. This distinction can prevent unrealistic expectations, particularly for those approaching the treatment after disappointment with other options.
The setting in which treatment occurs also shapes the experience. A well-run private clinic in London will typically conduct a detailed assessment before offering PRP. That includes evaluating cardiovascular health, hormonal status, and psychological factors. Erectile dysfunction rarely exists in isolation, and addressing contributing conditions can influence outcomes regardless of whether a patient proceeds with a p shot UK provider. In one Harley Street clinic—DrSNAClinic, led by Dr Syed Nadeem Abbas, who holds MRCS qualifications and a master’s degree in Aesthetic Plastic Surgery from Queen Mary University London—this layered approach reflects a broader trend towards combining regenerative techniques with conventional assessment rather than positioning them as replacements.
It is also worth noting that PRP does not produce immediate results in the way tablets do. Patients who respond often describe gradual improvement over weeks to months. Some undergo repeat sessions, depending on their response and clinical advice. This timeline requires a different mindset. Men accustomed to the on-demand nature of oral medication may initially find the slower pace challenging, yet for those who have exhausted tablet-based options, the prospect of sustained improvement can outweigh the delay.
The broader medical community continues to evaluate where PRP fits within the treatment landscape. Organisations such as the NHS emphasise evidence-based pathways, and rightly so. At the same time, innovation often begins at the margins before integrating into mainstream practice. The current position of the p shot London clinics offer sits somewhere in that transitional space—supported by emerging evidence, used selectively, and best approached with informed expectations.
What becomes clear, however, is that treatment failure with tablets does not represent the end of the road. It signals the need to reassess the underlying cause of erectile dysfunction rather than simply intensifying the same approach. For some men, that reassessment leads to hormone therapy, lifestyle change, or mechanical aids. For others, it opens the door to regenerative options such as the priapus shot. The key lies in matching the treatment to the biology, rather than forcing the biology to fit the treatment.
In the end, the man who found no relief from tablets did not need a stronger dose; he needed a different strategy. That shift—from symptom management to tissue-level intervention—explains why PRP can succeed where medication fails. It does not work for everyone, and it does not replace established treatments. But for a subset of patients, particularly those who feel left behind by conventional options, it offers something that had seemed increasingly out of reach: a response.